Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study05/15/2019 - 12/31/2021 (Subcontract PI)
University of Southern California NIH NIA1R01AG063689-01
Tau PET Imaging for the USC Alzheimer's Therapeutic Research Institute (USC ATRI) A4 Trial (“A4 TAU”)10/01/2016 - 12/31/2021 (Subcontract PI)
University of Southern California Fundation for NIH
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)12/11/2015 - 12/31/2021 (Subcontract PI)
University of Southern California Eli Lilly and Co
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study11/01/2015 - 10/31/2021 (Subcontract PI)
University of Southern California Alzheimer's Assoc
Genomics Institute of the Novartis Research Foundation--Research Contract05/01/2019 - 05/01/2021 (PI)
Novartis Institute for Functional Genomics, Inc., dba the Genomics Institute of the Novartis Research Foundation
Metformin in Alzheimer's dementia Prevention (MAP)09/15/2020 - 04/30/2021 (Subcontract PI)
Trustees Of Columbia University In The City Of New York NIH NIA3R01AG062624-02S1
A placebo-controlled, double-blind, parallel-group, bayesian adaptive randomization design and dose regimen-finding study to evaluate the safety tolerability and efficacy of BAN2401 in subjects with02/01/2013 - 08/04/2020 (PI)
Eisai, Inc
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials ("RAmP" or 18F-AV-45-A25)03/20/2017 - 03/19/2020 (PI)
Avid Radiopharmaceuticals, Inc.
Alzheimer's Disease Cooperative Study - A4 Study12/01/2015 - 02/29/2020 (Subcontract PI)
University of Southern California NIH NIA5U19AG010483-26
An Open label, multicenter study evaluating the imaging characteristics of a follow up F-AV-1451 scan in subjects that participated in the confirmatory cohort of FV-AV-1451-A0509/29/2016 - 09/28/2018 (PI)
Avid Radiopharmaceuticals, Inc.
Measuring Glial metabolism in repetitive brain trauma and Alzheimer's Disease08/15/2015 - 08/14/2018 (Subcontract PI)
The Brigham and Women's Hospital, Inc. DOD Army Med Resrch
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia (The DAYBREAK Study)10/24/2016 - 06/12/2018 (PI)
Eli Lilly and Company
An open label, multicenter study, evaluating the safety and imaging characteristics of 18F-AV-1451 in cognitively healthy volunteers, subjects with Mild Cognitive Impairment, and subjects with Alzheim03/01/2014 - 05/31/2018 (PI)
Avid Radiopharmaceuticals, Inc.
A Phase 2 multi-center, randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T-817MA in patients with mild to moderate Alzheimer's Disease (US202)11/21/2013 - 05/31/2018 (Subcontract PI)
The Regents of the University of California Toyama Chemical Co.
Protocol # 54861911ALZ2003, A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigation the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymp10/27/2017 - 05/17/2018 (PI)
Janssen Research & Development, LLC
Magnetic Resonance Spectroscopy as a Biomarker for Chronic Traumatic Encephalopathy05/01/2016 - 04/30/2018 (Multi-PI)
PI:
Robert A. Stern, PhDNIH/National Institute of Neurological Disorders & Stroke5F32NS096803-02
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo12/01/2013 - 04/30/2017 (PI)
Eli Lilly and Company
DoD Traumatic Brain Injury Research Award09/30/2013 - 09/29/2016 (PI)
Department of Defense
Amarantus LymPro Cell Cycle dysfunction Blood biomarker for AD and CTE06/16/2014 - 06/15/2016 (PI)
Amarantus Holdings, Inc.
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (Study A4)12/31/2012 - 05/31/2016 (Subcontract PI)
University of California, San Diego NIH NIA5U01AG010483-24
Risk of Cognitive Decline in Older Breast Cancer Patients10/01/2009 - 04/30/2016 (Subcontract PI)
Georgetown University NIH NCI5R01CA129769-05
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (Study A4)12/31/2012 - 04/27/2016 (Subcontract PI)
University of California, San Diego NIH NIA5U01AG010483-24
Chronic Traumatic Encephalopathy: Clinical Presentation and Biomarkers09/30/2014 - 02/29/2016 (PI)
NIH/National Institute of Neurological Disorders & Stroke2R56NS078337-04
18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects with Repetitive Brain Trauma at High Risk for Chronic Traumatic Encephalopathy03/01/2014 - 09/01/2015 (PI)
Avid Radiopharmaceuticals, Inc.
Diagnosing and Evaluating Traumatic Encephalopathy using Clinical Tests01/01/2012 - 12/31/2014 (PI)
Brainscope Company, Inc
Diagnosing and Evaluating Traumatic Encephalopathy using Clinical Tests01/01/2012 - 12/31/2014 (PI)
Brainscope Company, Inc
A Phase 3 Extension, Multicenter, Long-term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Carriers and Participated12/01/2011 - 11/30/2014 (PI)
Pfizer, Inc.
Chronic Traumatic Encephalopathy: Clinical Presentation and Biomarkers08/01/2011 - 09/29/2014 (PI)
NIH/National Institute of Neurological Disorders & Stroke5R01NS078337-03
Subclinical Hypothyroidism: Mood, Cognition and the Effect of L-Thyroxine Treatment09/30/2008 - 05/31/2014 (PI)
NIH/National Institute of Mental Health5R01MH080295-05
CONCERT PLUS: An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating Dimebon (Laterpirdine) in Patients with Alzheimer's Disease Phase 3 Multicenter, Randomized, Placebo-Controlled,08/01/2010 - 07/31/2013 (PI)
Medivation, Inc.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Efficacy Safety Trial of Bapinevzumb (AAB-001, ELN115727) in subjects with Mild to Moderate Alzheimer Disease05/01/2011 - 04/30/2013 (PI)
Wyeth Pharmaceuticals
A Phase 3, Multicenter, Parallel-Group, Long Term Safety and Tolerabilty Treatment Trial of Bapineuzumab (AAB-001), ELN115727) in Subjects with AD Who Participated in Study ELN115727-301 or in St12/01/2009 - 04/30/2013 (PI)
Janssen Pharmaceutica (Belgium)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab11/01/2009 - 04/30/2013 (PI)
Wyeth Pharmaceuticals
ADCS Infrastructure Support01/01/2012 - 12/31/2012 (Subcontract PI)
The Regents of the University of California NIH NIA5U01AG010483-21
Multi-Centrial to Evaluate Home-Based Assessment Methods for Alzheimer's Disease Prevention Research in People over 75 Years Old09/01/2007 - 12/31/2012 (Subcontract PI)
University of California, San Diego NIH NIA
Prevention of Alzheimer's Disease and Cognitive Decline09/01/2009 - 07/31/2012 (Subcontract PI)
Seattle Institute for Biomedical and Clinical Research NIH NIA
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Patients with Mild to Moderate Alzheimer's04/01/2008 - 03/31/2012 (PI)
Elan Pharmaceuticals, Inc.
Assessment of Driving Safety in Aging, MCI and Dementia03/01/2009 - 02/29/2012 (PI)
Alzheimer's Association
Objective Biomarkers for Alzheimer's Disease in the Retina12/01/2009 - 11/30/2011 (Subcontract PI)
Mass Eye and Ear Infirmary Other Fdns/Societies
Effect of Gama Sectretase Inhibition on the Progression on AD: LY 450139 Versus Placebo, Control H6L-MC-LFAN12/01/2008 - 11/30/2011 (PI)
Eli Lilly and Company, Lilly Research Laboratories
Effect of Gamma Secretase Inhibition on the Progression on AD: LY 450139 Versus Placebo, Control H6L-MC-LFAN12/01/2008 - 11/30/2011 (PI)
Lilly Research Laboratories (Division of Eli Lilly and Company)
Driving and Dementia11/01/2004 - 10/31/2006 (PI)
Massachusetts Institute of Technology Hartford Fin Svcs Gr